N-myc/Alpha Satellite 2
Neuroblastoma is predominantly a tumor of early childhood.
Hyperdiploid tumor DNA is associated with a favorable prognosis,
especially in infants with neuroblastoma, while N-myc
amplification is associated with a poor prognosis regardless of patient age. In contrast to N-myc gene amplification, the
degree of expression of the N-myc gene in the tumor does not
Amplification of the N-myc (MYCN) proto-oncogene occurs in
20% to 25% of neuroblastomas and is a reliable marker of
aggressive clinical behavior. Consistent areas of chromosomal
loss, including chromosome band 1p36 in 30% to 35% of primary tumors, 11q23 in 44%, and 14q23-qter in 22%, may
identify the location of neuroblastoma suppressor genes.
The Qbiogene probe for N-myc uses the Universal Linkage
System (ULS®) and is optimized to detect amplification of the
N-myc gene region. The included Chromosome 2 Alpha-Satellite probe serves as internal control and simultaneously defines the ploidy status of Chromosome 2.
This direct labeled probe has been tested and qualified on cultured
cells, blood smears and are optimized for formalin-fixed
paraffin-embedded tissue sections.
The 2p24 N-myc(MYCN) specific DNA Probe is direct-labeled with Rhodamine (Exc max. 565
nm; Em. max. 590 nm). the Chromosome 2 Alpha-Satellite Probe is direct-labeled with
Fluorescein (Exc. Max. 495 nm; Em max. 525 nm). The “RF” in the catalog number refers to
patented repeat free “SET” technology used in this probe.
Gene: N-myc (MYCN)
Probe Size : 300 kb